These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 33054078)

  • 1. Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance.
    Conran N; De Paula EV
    Haematologica; 2020 Oct; 105(10):2380-2390. PubMed ID: 33054078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle Cell Disease and Thromboembolism: New Insights on the Pathophysiology, Diagnosis, and Treatment.
    Dobie G
    Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.
    Nader E; Conran N; Romana M; Connes P
    Compr Physiol; 2021 Apr; 11(2):1785-1803. PubMed ID: 33792905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sickle cell vaso-occlusion: The dialectic between red cells and white cells.
    Conran N; Embury SH
    Exp Biol Med (Maywood); 2021 Jun; 246(12):1458-1472. PubMed ID: 33794696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypercoagulability in Sickle Cell Disease: A Thrombo-Inflammatory Mechanism.
    Hamali HA
    Hemoglobin; 2023 Nov; 47(6):205-214. PubMed ID: 38189099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
    Nader E; Romana M; Connes P
    Front Immunol; 2020; 11():454. PubMed ID: 32231672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of Sickle Cell Disease.
    Sundd P; Gladwin MT; Novelli EM
    Annu Rev Pathol; 2019 Jan; 14():263-292. PubMed ID: 30332562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving treatment paradigms in sickle cell disease.
    Jagadeeswaran R; Rivers A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):440-446. PubMed ID: 29222291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease.
    Nyffenegger N; Zennadi R; Kalleda N; Flace A; Ingoglia G; Buzzi RM; Doucerain C; Buehler PW; Schaer DJ; Dürrenberger F; Manolova V
    Blood; 2022 Aug; 140(7):769-781. PubMed ID: 35714304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombosis and sickle cell disease.
    De Franceschi L; Cappellini MD; Olivieri O
    Semin Thromb Hemost; 2011 Apr; 37(3):226-36. PubMed ID: 21455857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Sickle Cell Disease Therapies: Targeting Pathways Downstream of Sickling.
    Morrone K; Mitchell WB; Manwani D
    Semin Hematol; 2018 Apr; 55(2):68-75. PubMed ID: 30616808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation in Sickle Cell Disease: Differential and Down-Expressed Plasma Levels of Annexin A1 Protein.
    Torres LS; Okumura JV; Silva DG; Mimura KK; Belini-Júnior É; Oliveira RG; Lobo CL; Oliani SM; Bonini-Domingos CR
    PLoS One; 2016; 11(11):e0165833. PubMed ID: 27802331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular pathophysiology of sickle cell disease.
    Connes P; Renoux C; Joly P; Nader E
    Presse Med; 2023 Dec; 52(4):104202. PubMed ID: 37944640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation in sickle cell disease.
    Conran N; Belcher JD
    Clin Hemorheol Microcirc; 2018; 68(2-3):263-299. PubMed ID: 29614637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroke and presence of patent foramen ovale in sickle cell disease.
    Aggeli C; Polytarchou K; Dimitroglou Y; Patsourakos D; Delicou S; Vassilopoulou S; Tsiamis E; Tsioufis K
    J Thromb Thrombolysis; 2021 Oct; 52(3):889-897. PubMed ID: 33638018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk of Inflammation and Coagulation in
    Cavalcante JS; de Almeida DEG; Santos-Filho NA; Sartim MA; de Almeida Baldo A; Brasileiro L; Albuquerque PL; Oliveira SS; Sachett JAG; Monteiro WM; Ferreira RS
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The APC-EPCR-PAR1 axis in sickle cell disease.
    Ramadas N; Sparkenbaugh EM
    Front Med (Lausanne); 2023; 10():1141020. PubMed ID: 37497271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of blood rheology in sickle cell disease.
    Connes P; Alexy T; Detterich J; Romana M; Hardy-Dessources MD; Ballas SK
    Blood Rev; 2016 Mar; 30(2):111-8. PubMed ID: 26341565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative stress in sickle cell disease; more than a DAMP squib.
    van Beers EJ; van Wijk R
    Clin Hemorheol Microcirc; 2018; 68(2-3):239-250. PubMed ID: 29614635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophils as drivers of vascular injury in sickle cell disease.
    Torres LS; Hidalgo A
    Immunol Rev; 2023 Mar; 314(1):302-312. PubMed ID: 36251624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.